Ballyshannon Woman First in World to Get New Procedure
Groundbreaking Recana System Offers New Hope for Chronic Venous Disease Patients
Table of Contents
Galway, Ireland – A revolutionary new medical device, the Recana system, is transforming the treatment landscape for patients suffering from complex chronic venous disease, particularly those experiencing re-narrowing of veins after stenting. This minimally invasive technology,successfully trialed for the first time globally at University Hospital Galway,offers a beacon of hope for individuals who have weary conventional treatment options.
A New Dawn in venous Treatment
The recana system is designed to address a critical challenge in vascular care: restenosis, a condition where veins narrow again after stenting. This innovative device is inserted through a small incision, typically in the leg, allowing clinicians to precisely access and clear previously obstructed veins. By restoring healthy blood flow, the Recana system promises to substantially improve the quality of life for patients grappling with the debilitating effects of chronic venous disease.
first patient Hails life-Changing Results
The pioneering procedure was first administered to Kelly Coughlin from Ballyshannon, County Donegal. Her prosperous treatment represents a meaningful milestone in the management of chronic venous disease and underscores the power of collaboration between leading healthcare and research institutions. The initiative involved University Hospital Galway, University of Galway’s Institute for Clinical Trials, and InterVene, Inc., the developers of the recana system.
professor Gerry O’Sullivan, consultant Interventional Radiologist at University hospital Galway, who led the procedure, expressed his enthusiasm for the technology. “This marks a significant advancement in the treatment of chronic venous disease,” he stated. “The long-term impact of venous obstructions,especially in previously stented vessels,can be life-altering. I had attempted to recanalize this patient’s veins four times without success. The Recana system achieved this in a single session. That speaks volumes about its potential.”
Professor O’Sullivan further emphasized the system’s value, adding, “It offers a powerful, minimally invasive solution for patients who have exhausted conventional treatment options.”
Kelly Coughlin shared her personal experience, describing the treatment as “massively life changing.” She elaborated, “When I was symptomatic, even simple tasks like walking were a challenge. I’m incredibly grateful to Professor O’Sullivan and his team at University Hospital Galway. I’ve been under his care for manny years, and that long-standing trust gave me the confidence and reassurance I needed to proceed with this treatment.”
A Triumph of Collaboration and Innovation
The successful global trial of the Recana system at University Hospital Galway highlights the institution’s commitment to clinical excellence and innovation. Chris Kane, Hospital Manager, praised the achievement, stating, “This is a significant achievement for University Hospital Galway and reflects our unwavering commitment to clinical excellence and innovation. Being the first in the world to trial this ground-breaking device showcases both the expertise of our medical teams and the strength of our collaborative research partnerships.”
Professor Fidelma Dunne, Director of the Institute for Clinical Trials at University of Galway, lauded the collaborative success. “It is incredibly rewarding to see cutting-edge medical device innovation introduced in Ireland through the Hypercare initiative at university of Galway’s Institute for clinical Trials,” she commented. “Hypercare was developed to streamline and accelerate the start-up of clinical trials by working closely with our regulatory, ethical, and healthcare delivery partners. This milestone is a clear reflection of that mission in action.”
This groundbreaking procedure firmly positions University Hospital Galway at the forefront of global medical innovation, clinical research, and collaborative healthcare, setting a new standard in the treatment of complex venous disease.